CD19-specific Chimeric Antigen Receptor (CAR) T-cell products and bispecific T-cell engagers (BiTE) are approved for relapsed and refractory B-cell neoplasms. However, rapid disease progression and the pre-treatment workflow during CAR T-cell manufacturing challenges several specialities of health care professionals and involves a well-educated team in the inpatient and outpatient setting. In addition, CARs and BiTEs are accompanied by a new spectrum of immune related toxicities that significantly differ from toxicities known from chemotherapy or even checkpoint blockade.
Currently, clinical trials investigate the safety of outpatient CAR T-cell administration, requiring comprehensive monitoring and high-level patient care during the early post-infusion period. We have developed the interactive smartphone application “myTcell” to support the optimal management of these patients and to save time in clinical practice. “myTcell” educates physicians in logistics of CARs and BiTEs and and comes with interactive tools for grading and management of toxicities to increase guideline adherence, accelerate broader application and improve outcomes. “myTcell” will is available in Europe in the App Stores for iOS and Android and for Desktop.
More information: [ Ссылка ]
